Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial
Pharmacology, Toxicology and Pharmaceutical Science
8
7%
Biochemistry, Genetics and Molecular Biology
5
4%
Engineering
3
3%
Other
9
8%
Unknown
52
44%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 July 2024.
All research outputs
#3,508,213
of 34,411,289 outputs
Outputs from Diabetes, Obesity & Metabolism
#1,071
of 6,085 outputs
Outputs of similar age
#59,937
of 490,114 outputs
Outputs of similar age from Diabetes, Obesity & Metabolism
#34
of 77 outputs
Altmetric has tracked 34,411,289 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,085 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.6. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 490,114 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 77 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
